A pharmacological review of raloxifene

Journal of Bone and Mineral Metabolism

Volumn 14, Issue 1, 1996, Pages 1-9

  Bryant, Henry U ^a   Glasebrook, Andrew L ^a   Yang, Na N ^a   Sato, Masahiko ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bone; Breast cancer; Cholesterol; Estrogen; Raloxifene; Uterus

Indexed keywords

EID: 0002348234     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01771666     Document Type: Article

References (14)

1. Lindsay R, Aitken JM, Anderson JB (1976) Long-term prevention of post-menopausal osteoporosis by estrogen. Lancet 1:1038-1041
2. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Post-menopausal estrogen therapy, and cardiovascular disease: Ten-year follow-up from the nurses health study. N Engl J Med 325:756-762
3. Wiznitzer I, Benz C (1983) Tamoxifen vs. LY156758 for treatment of human breast and prostate cancer in vitro (abstract). Breast Cancer Res Treat. 3:305
4. Wakeling AE, Valcaccia B, Newboult E, Green LR (1984) Nonsteroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 20:111-120
5. Sato M, Glasebrook AL, Bryant HU (1995) Raloxifene: A selective estrogen receptor modulator. J Bone Miner Met 12 [Suppl II]:S9-S20
6. Labrie F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S. Dumont M, Hatton AC, Poirier D, Merand Y (1990) Interactions between estrogens, androgens, progestins and glucocorticoids in ZR-75-1 human breast cancer cells. Ann NY Acad Sei 595:130-148
7. Labrie F, Veilleux R, Fournier A (1988) Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture. Molec Cell Endocrinol 58:207-211
8. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin OR, Dickson RB, Lippman ME (1988) Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 48:6764-6768
9. Clemens JA, Bennett DR, Black LJ, Jones CD (1983) Effects of a new anti-estrogen, keoxifene LY156758, on growth of carcinogeninduced mammary tumors and on LH and prolactin levels. Life Sei 32:2869-2875
10. Wakeling AE, Valcaccia B (1983) Antioestrogenic and antitumor activities of a series of non-steroidal antioestrogens. J Endocr 99:455-464
11. Gottardis MM, Jordan VC(1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024
12. Buzdar AU, Marcus C. Holmes F, Hug V, Hortobagyi G (1988) Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45:344-345
13. Nicholson RI, Gotting KE, Gee J, Walker KJ (1988) Actions of oestrogens and antioestrogens on rat mammary gland development: Relevance to breast cancer prevention. J Steroid Biochem 30:95-103
14. Kleinberg DI, Todd J, Babitsky G (1983) Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: Reversal by antiestrogens LY156758 and tamoxifen. Proc Natl Acad Sei USA 80:4144-4148